According to Zacks, “Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women’s health. The company’s product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey. “
Other analysts have also recently issued research reports about the company. ValuEngine cut Osmotica Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, May 27th. Royal Bank of Canada reaffirmed a buy rating and set a $10.00 target price on shares of Osmotica Pharmaceuticals in a report on Wednesday, March 25th. SunTrust Banks assumed coverage on shares of Osmotica Pharmaceuticals in a report on Wednesday, March 18th. They issued a buy rating and a $8.00 price target on the stock. SVB Leerink initiated coverage on shares of Osmotica Pharmaceuticals in a research note on Friday, March 6th. They set an outperform rating and a $10.00 price objective for the company. Finally, Wells Fargo & Co downgraded shares of Osmotica Pharmaceuticals from an overweight rating to an equal weight rating and set a $4.00 price objective on the stock. in a report on Monday, March 23rd. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $7.79.
Osmotica Pharmaceuticals (NASDAQ:OSMT) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.07. Osmotica Pharmaceuticals had a negative net margin of 115.34% and a negative return on equity of 6.22%. The business had revenue of $48.65 million for the quarter, compared to analyst estimates of $43.76 million. As a group, research analysts anticipate that Osmotica Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.
Large investors have recently made changes to their positions in the business. New York State Common Retirement Fund grew its stake in shares of Osmotica Pharmaceuticals by 2,630.2% during the 4th quarter. New York State Common Retirement Fund now owns 13,651 shares of the company’s stock worth $95,000 after purchasing an additional 13,151 shares during the period. State Street Corp lifted its stake in shares of Osmotica Pharmaceuticals by 20.4% in the 4th quarter. State Street Corp now owns 145,299 shares of the company’s stock valued at $1,016,000 after purchasing an additional 24,617 shares during the period. State of Tennessee Treasury Department purchased a new stake in Osmotica Pharmaceuticals during the fourth quarter worth $26,000. Martingale Asset Management L P acquired a new stake in Osmotica Pharmaceuticals during the fourth quarter valued at $336,000. Finally, Barclays PLC grew its position in Osmotica Pharmaceuticals by 103.0% during the fourth quarter. Barclays PLC now owns 8,226 shares of the company’s stock valued at $57,000 after buying an additional 4,174 shares during the period. 14.37% of the stock is owned by institutional investors.
About Osmotica Pharmaceuticals
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.
Featured Story: Equity Income
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.